Literature DB >> 25457209

Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.

You Zhou1, Gemma Llauradó2, Matej Orešič3, Tuulia Hyötyläinen3, Marju Orho-Melander4, Hannele Yki-Järvinen5.   

Abstract

BACKGROUND & AIMS: The Glu167Lys (E167K) variant in the transmembrane 6 superfamily member 2 protein (TM6SF2) was recently shown to influence liver fat (LFAT) content. We aimed at studying how this variant influences circulating triacylglycerol (TAG) signatures and whether it influences hepatic or adipose tissue insulin sensitivity.
METHODS: We genotyped 300 Finnish subjects for the E167K (rs58542926) variant in TM6SF2 and for the I148M (rs738409) variant in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) in whom LFAT was measured using 1H-MRS and circulating lipids by UPLC-MS. We compared the plasma lipidome between E167K carriers (TM6SF2EK/KK) and non-carriers (TM6SF2EE), and between three groups of NAFLD: (i) carriers of the E167K but not of the I148M variant in PNPLA3 ('TM6SF2 NAFLD'), (ii) carriers of the I148M but not of the E167K variant ('PNPLA3 NAFLD'), and (iii) non-carriers of either risk allele ('Non-risk NAFLD'). Hepatic and adipose tissue insulin sensitivities were measured using the euglycemic hyperinsulinemic clamp technique combined with infusion of [3-3H]glucose in 111 subjects.
RESULTS: The LFAT content was 34% higher in the TM6SF2EK/KK (13.07±1.57%) than in the TM6SF2EE group (9.77±0.58%, p=0.013). The effect of insulin on glucose production and lipolysis were significantly higher in the TM6SF2EK/KK than in the TM6SF2EE group. Comparison of the three NAFLD groups with similar LFATs showed that both the 'TM6SF2 NAFLD' and 'PNPLA3 NAFLD' had significantly lower triglyceride levels and were characterized by lower levels of most common TAGs compared to the 'Non-risk NAFLD' group.
CONCLUSIONS: We conclude that the E167K variant in TM6SF2 is associated with a distinct subtype of NAFLD, characterized by preserved insulin sensitivity with regard to lipolysis, hepatic glucose production and lack of hypertriglyceridemia despite a clearly increased LFAT content.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glucose production; Lipolysis; Liver; Magnetic resonance spectroscopy; Mass spectrometry

Mesh:

Substances:

Year:  2014        PMID: 25457209     DOI: 10.1016/j.jhep.2014.10.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  42 in total

1.  Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study.

Authors:  Anna Viitasalo; Jussi Pihlajamäki; Jussi Paananen; Mustafa Atalay; Virpi Lindi; Timo A Lakka
Journal:  Pediatr Res       Date:  2016-01-12       Impact factor: 3.756

Review 2.  Genetics of alcoholic liver disease and non-alcoholic steatohepatitis.

Authors:  Emma Scott; Quentin M Anstee
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

3.  Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.

Authors:  Marcin Krawczyk; Monika Rau; Jörn M Schattenberg; Heike Bantel; Anita Pathil; Münevver Demir; Johannes Kluwe; Tobias Boettler; Frank Lammert; Andreas Geier
Journal:  J Lipid Res       Date:  2016-11-11       Impact factor: 5.922

Review 4.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

5.  Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study.

Authors:  Xiaoping Tang; Yanyan Shi; Juan Du; Keming Hu; Tingting Zhou; Lan Chen; Yanming Zhang; Fujun Li; Huier Zhang; Roman Liebe; Christoph Meyer; Steven Dooley; Zhongwei Zhu; Hong-Lei Weng; Jinzhu Jia; Tong Huang
Journal:  BMJ Open       Date:  2022-06-27       Impact factor: 3.006

Review 6.  Diagnosis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2016-04-18       Impact factor: 10.122

Review 7.  Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.

Authors:  Bérénice Charrez; Liang Qiao; Lionel Hebbard
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 8.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Authors:  Mojgan Masoodi; Amalia Gastaldelli; Tuulia Hyötyläinen; Enara Arretxe; Cristina Alonso; Melania Gaggini; Julia Brosnan; Quentin M Anstee; Oscar Millet; Pablo Ortiz; Jose M Mato; Jean-Francois Dufour; Matej Orešič
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-10       Impact factor: 46.802

Review 9.  Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?

Authors:  Brian N Finck; Angela M Hall
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

Review 10.  Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative.

Authors:  Maria de Fátima Brito; Carla Torre; Beatriz Silva-Lima
Journal:  Front Med (Lausanne)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.